April 2, 2009 - McKesson’s releases its 2009 InterQual Criteria and CareEnhance Review Manager 8.0 software features industry-leading innovations including molecular and genetic diagnostics criteria.
The new criteria, combined with the option for clients to access it via McKesson’s recently launched auto authorization capability, is designed to increase the value of the content for users while helping improve quality of care for patients.
“As we bring the latest versions of our criteria and software to market, we are focused on driving efficiencies for payors and providers while expanding into new content areas,” said Tammie Phillips, vice president of InterQual for McKesson Health Solutions. “Even as we address major industry issues with our new auto authorization functionality and molecular diagnostics content, we continue to enhance and add value to the existing elements of our solution suite that have made it the gold standard in evidence-based clinical decision support.”
McKesson’s auto authorization is a hosted, Web-based offering that leverages McKesson’s new Advanced Diagnostics Management solution. The offering automates the entire authorization process, from the initial request all the way through final authorization. McKesson’s auto authorization capability can incorporate InterQual Molecular Diagnostics Criteria and select Imaging Criteria—and soon selected Procedures Criteria—so that medical appropriateness is determined automatically for most requests. The content plus technology drive reduced administrative costs, better payor-provider relations and support optimal care.
The new InterQual Molecular Diagnostics Criteria is an important innovation included in this release. McKesson provides a comprehensive set of criteria to support decision-making for molecular diagnostic tests.
Molecular Diagnostics Criteria is updated quarterly so it is always current. To help healthcare organizations determine test appropriateness based on clinical evidence, InterQual Molecular Diagnostics Criteria covers over 225 tests that comprise approximately 85 percent of the costs in this growing area. A new question and answer format leads to service recommendations that include alternative and concurrent tests, allowing users to easily conduct reviews and act on information. In addition, pop-up notes and clinical evidence summaries drive evidence-based medicine to the point of decision-making with more efficiency. The content is available in CareEnhance Review Manager software as well as McKesson’s Advanced Diagnostics Management solution auto authorization capability.
For more information: www.mckesson.com
April 10, 2024 
![(A) PET images of [68Ga]Ga-DOTA-ZCAM241 uptake at baseline and 3, 7, and 12 days after injection as inflammatory arthritis developed in single representative individual mouse. Images are normalized to SUV of 0.5 for direct comparison between time points. (B) CD69 immunofluorescence Sytox (Thermo Fisher Scientific) staining of joints of representative animals during matching time points.](/sites/default/files/styles/feed_medium/public/PET%20Tracers.jpeg?itok=P5Di6MIe)
